​The National Neuroscience Institute (NNI) has signed a memorandum with German pharmaceutical company Schwabe Pharma for a two-year collaboration. NNI will conduct a clinical trial to investigate whether ginkgo biloba extract can treat mild cognitive impairment to prevent dementia. The study will begin in the fourth quarter of this year and is expected to draw conclusions in the third quarter two years later. Assoc Prof Nagaendran Kandiah, Senior Consultant, Department of Neurology, NNI, who is charge of this study, shared that EGb 761 is a patented standardised extract from the leaves of Ginkgo biloba, which has been shown in previous studies to improve blood circulation in the brain. 

Click here for the full article in Mandarin.

Source: Lianhe Zaobao (c) Singapore Press Holdings Limited. Permission required for reproduction.